| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A model of vector-targeted interventions for visceral leishmaniasis
|
Petersen, Christine
|
|
|
24 |
11 |
p. 1187-1188
|
artikel
|
| 2 |
Antiviral therapy for patients with COVID-19: mix and match
|
Akinosoglou, Karolina
|
|
|
24 |
11 |
p. 1179-1181
|
artikel
|
| 3 |
A promising boost for the Rift Valley fever vaccine pipeline
|
Bronder, Saskia
|
|
|
24 |
11 |
p. 1184-1185
|
artikel
|
| 4 |
ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies
|
Whelan, Mairead G
|
|
|
24 |
11 |
p. e670-e671
|
artikel
|
| 5 |
A shared history
|
Lenahan, Claire
|
|
|
24 |
11 |
p. 1199
|
artikel
|
| 6 |
Boosting immunity to protect from tickborne Lyme disease
|
Baumgarth, Nicole
|
|
|
24 |
11 |
p. 1188-1190
|
artikel
|
| 7 |
Cholera in Sudan amid war and health system collapse
|
Boisson-Walsh, Alix
|
|
|
24 |
11 |
p. e681
|
artikel
|
| 8 |
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
|
Choi, Ming Hong
|
|
|
24 |
11 |
p. 1213-1224
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1
|
|
|
|
24 |
11 |
p. e678
|
artikel
|
| 10 |
COVID-19 and sexual health rights in Africa
|
Ramgolam, Aimee
|
|
|
24 |
11 |
p. 1200
|
artikel
|
| 11 |
Edging towards a third dengue vaccine
|
Wilder-Smith, Annika B
|
|
|
24 |
11 |
p. 1182-1184
|
artikel
|
| 12 |
Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study
|
Coffeng, Luc E
|
|
|
24 |
11 |
p. 1266-1274
|
artikel
|
| 13 |
Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil
|
Nogueira, Mauricio L
|
|
|
24 |
11 |
p. 1234-1244
|
artikel
|
| 14 |
Equatorial Guinea intensifies its fight against tuberculosis
|
Bagcchi, Sanjeet
|
|
|
24 |
11 |
p. e682
|
artikel
|
| 15 |
Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance
|
Ishengoma, Deus S
|
|
|
24 |
11 |
p. 1225-1233
|
artikel
|
| 16 |
Financing infectious disease services in hospitals: a common public good
|
Tucker, Joseph D
|
|
|
24 |
11 |
p. e677
|
artikel
|
| 17 |
Globalisation and COVID-19
|
Lawson, Matilda
|
|
|
24 |
11 |
p. 1198
|
artikel
|
| 18 |
High-Level Meeting on Antimicrobial Resistance 2024
|
Burki, Talha
|
|
|
24 |
11 |
p. e684-e685
|
artikel
|
| 19 |
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination
|
Happle, Christine
|
|
|
24 |
11 |
p. e674-e676
|
artikel
|
| 20 |
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
|
Ghadge, Santhosh Kumar
|
|
|
24 |
11 |
p. 1275-1286
|
artikel
|
| 21 |
Infectious disease surveillance update
|
McQuillan, Cahal
|
|
|
24 |
11 |
p. e686
|
artikel
|
| 22 |
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade
|
Moore, Kristine A
|
|
|
24 |
11 |
p. e696-e706
|
artikel
|
| 23 |
Lessons learnt from conducting a randomised clinical trial in eumycetoma
|
Sprute, Rosanne
|
|
|
24 |
11 |
p. 1186-1187
|
artikel
|
| 24 |
Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity
|
Jones, Toby
|
|
|
24 |
11 |
p. e660-e661
|
artikel
|
| 25 |
Médecins Sans Frontières ceases activity in Russia
|
Holt, Ed
|
|
|
24 |
11 |
p. e683
|
artikel
|
| 26 |
Measures to prevent and treat Nipah virus disease: research priorities for 2024–29
|
Moore, Kristine A
|
|
|
24 |
11 |
p. e707-e717
|
artikel
|
| 27 |
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
|
Gray, Glenda E
|
|
|
24 |
11 |
p. 1201-1212
|
artikel
|
| 28 |
Mpox—is there a more dangerous new clade?
|
Hoffmann, Christian
|
|
|
24 |
11 |
p. e667
|
artikel
|
| 29 |
Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions
|
Bapolisi, Wyvine Ansima
|
|
|
24 |
11 |
p. e672-e673
|
artikel
|
| 30 |
Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis
|
Pillet, Sylvie
|
|
|
24 |
11 |
p. 1192-1194
|
artikel
|
| 31 |
Nathan Lo—translating infectious disease models into policy
|
Kirby, Tony
|
|
|
24 |
11 |
p. 1196
|
artikel
|
| 32 |
Oropouche fever: reports of vertical transmission and deaths in Brazil
|
Martins-Filho, Paulo Ricardo
|
|
|
24 |
11 |
p. e662-e663
|
artikel
|
| 33 |
Oropouche virus genomic surveillance in Brazil
|
Moreira, Filipe Romero Rebello
|
|
|
24 |
11 |
p. e664-e666
|
artikel
|
| 34 |
Potential vertical transmission of Oropouche virus during the current outbreak
|
Samara, Athina
|
|
|
24 |
11 |
p. e668-e669
|
artikel
|
| 35 |
Rare presentation of rapidly progressive tertiary syphilis in AIDS: a case report of syphilitic gumma
|
Peng, Bin
|
|
|
24 |
11 |
p. e724
|
artikel
|
| 36 |
Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review
|
Shirini, Kasra
|
|
|
24 |
11 |
p. e718-e723
|
artikel
|
| 37 |
Research in brief
|
Venkatesan, Priya
|
|
|
24 |
11 |
p. e687
|
artikel
|
| 38 |
Resistant malaria parasites gaining momentum in Africa
|
Mlugu, Eulambius M
|
|
|
24 |
11 |
p. 1181-1182
|
artikel
|
| 39 |
Robert Salata
|
Bagcchi, Sanjeet
|
|
|
24 |
11 |
p. 1195
|
artikel
|
| 40 |
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial
|
Leroux-Roels, Isabel
|
|
|
24 |
11 |
p. 1245-1253
|
artikel
|
| 41 |
The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation–a consensus statement
|
Bijker, Else M
|
|
|
24 |
11 |
p. e688-e695
|
artikel
|
| 42 |
The need for novel approaches to HIV-1 vaccine development
|
Lehmann, Clara
|
|
|
24 |
11 |
p. 1178-1179
|
artikel
|
| 43 |
The responsibility of publishing early outbreak data
|
The Lancet Infectious Diseases,
|
|
|
24 |
11 |
p. 1177
|
artikel
|
| 44 |
The worsening mpox outbreak in Africa: a call to action
|
Kuppalli, Krutika
|
|
|
24 |
11 |
p. 1190-1192
|
artikel
|
| 45 |
15th Neglected Tropical Disease NGO Network conference
|
Jesudason, Timothy
|
|
|
24 |
11 |
p. e679
|
artikel
|
| 46 |
Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
|
Fahal, Ahmed H
|
|
|
24 |
11 |
p. 1254-1265
|
artikel
|
| 47 |
Vaccine hesitancy in Scandinavia
|
Sherwood-Martin, Hollie
|
|
|
24 |
11 |
p. 1197
|
artikel
|
| 48 |
WHO framework for investigating novel pathogens
|
Samarasekera, Udani
|
|
|
24 |
11 |
p. e680
|
artikel
|
Tijdschrift beschrijving